The APEX1 Knockout HeLa Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal cell population in which the APEX1 gene has been disrupted via target-gene disruption, creating a loss-of-function model for investigating the multifunctional roles of APEX1. This heterogeneous cell pool, derived from the HeLa cervical adenocarcinoma epithelial line, enables the study of gene function without single-cell cloning artifacts, maintaining biological variability relevant to cancer research. Researchers can use these polyclonal knockout cells as a tool for probing APEX1-dependent processes in DNA repair and redox signaling, with assays such as Western blotting and RT-qPCR recommended for confirming target disruption and downstream expression changes.
HeLa cells, isolated from a human cervical carcinoma and positive for human papillomavirus type 18 (HPV18), represent a widely employed cervical cancer model. These adherent epithelial cells express wild-type p53 that is functionally inactivated by the HPV E6 oncoprotein, leading to a compromised DNA damage response. Additionally, HeLa cells exhibit common aneuploidy and a robust proliferative capacity, characteristics that make them particularly suitable for studying genomic instability and drug resistance mechanisms. The APEX1 knockout in this background provides a platform to examine how the loss of a critical DNA repair and redox regulator intersects with HPV-driven oncogenesis and aneuploidy.
APEX1 encodes a dual-function protein that operates at the nexus of DNA base excision repair (BER) and redox regulation of transcription factors. Its AP endonuclease activity is essential for repairing abasic sites generated by spontaneous hydrolysis or by DNA-glycosylases, working in concert with XRCC1, PCNA, POL??, and DNA ligase III within the BER pathway. In parallel, APEX1 exerts redox control by reducing cysteine residues on transcription factors such as AP-1 (c-Jun/c-Fos), p53, and HIF-1??, thereby enhancing their DNA-binding activity and downstream gene expression. APEX1 is activated by upstream kinases ATM and ATR, and its expression is induced by oxidative stress (H2O2, ROS) through transcription factors Nrf2 and Sp1, as well as by MAPK and PI3K/AKT signaling pathways. Furthermore, APEX1 interacts with MDM2, NPM1, and NEDD8, placing it within a network that modulates cell cycle regulators, pro-inflammatory cytokines, and other DNA repair enzymes.
The HeLa cell context offers a unique backdrop for APEX1 knockout studies because the pre-existing p53 inactivation by HPV E6 likely exacerbates the genomic instability caused by compromised BER. Loss of APEX1 in these cells may dysregulate redox-sensitive transcription factors, altering the expression of genes controlled by p53, HIF-1??, and AP-1, and potentially sensitizing cells to chemotherapeutics that induce DNA base damage. The aneuploid nature of HeLa further amplifies the dependence on robust DNA repair, making this model valuable for dissecting synthetic lethal interactions with PARP1 inhibition or alkylating agents. This system is well-suited for exploring how DNA repair deficiency influences cervical cancer progression, metastasis, and treatment resistance.
These APEX1 knockout polyclonal HeLa cells are appropriate for a broad spectrum of functional and mechanistic studies. Typical applications include probing the biochemistry of base excision repair via co-immunoprecipitation of repair complexes (XRCC1/POL??), quantifying transcriptional responses through RNA-seq or RT-qPCR under oxidative stress, and assessing protein localization by immunofluorescence. Flow cytometry enables cell cycle and apoptosis profiling, while migration and invasion assays evaluate metastatic potential. Researchers can investigate drug sensitivity using agents such as alkylating compounds and PARP inhibitors, complemented by phospho-signaling analysis to map kinase pathway alterations. Metabolic assays further reveal shifts in redox homeostasis. For further details or technical specifications, please contact Ascent Research.
